AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
164.50
0.00 (0.00%)
Sep 7, 2025, 8:00 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
56.50B
Revenue Growth
+15.00%
P/S Ratio
4.45
Revenue / Employee
599.16K
Employees
94,300
Market Cap
251.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Longduoduo Company | 4.99M |
AstraZeneca News
- 17 hours ago - AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study - Benzinga
- 1 day ago - AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy - GuruFocus
- 2 days ago - TN signs MoUs with Hinduja, AstraZeneca - The Times of India
- 4 days ago - Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Benzinga
- 5 days ago - AstraZeneca, Corning And More On CNBC's 'Final Trades' - Benzinga
- 5 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 5 days ago - Final Trades: AstraZeneca, Corning, the IBIT and the SPHD - CNBC
- 6 days ago - Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success - GuruFocus